|
17 February 2008 Expert reacts to paper on new research into multiple sclerosis mechanisms
The research, published in the journal Nature, has revealed potential targets for the treatment of MS, which affects 85,000 people in the UK. The Science Media Centre asked a neurologist to comment on these new findings.
Professor Neil Scolding, University of Bristol Institute of Clinical Neurosciences, Department of Neurology, Frenchay Hospital, said:
"From the scientific perspective, the exciting thing is that it's pretty much the first time that proteomics has directly yielded a candidate molecule that is both unexpected and novel on the one hand AND has therapeutic potential.
"From the clinical perspective, showing that treatment approaches predicted by this proteomic interrogation of MS tissue do have a clear impact in experimental models of MS is extremely promising. As the authors point out, those treatments that interfere with blood coagulation 'would not be optimal because of the increased risk of bleeding', but this points the way to a new area of MS research of considerable interest, and which could well lead in the future to new lines of treatment."
To contact the above please contact the Science Media Centre on 020 7670 2980
Note for editors
The Science Media Centre (SMC) is an independent venture working to promote voices, stories and views from the scientific
community to the news media when science is in the headlines. Over 50 sponsors including scientific institutions, media groups,
corporate organisations and individuals fund the Centre, with donations capped at 5% of the running costs to preserve its independence.
The team at the Centre is guided by a respected Scientific
Panel and Board of
Advisors. This press release contains the personal
opinions of those acknowledged; which represent neither the views of the SMC nor any other organisation unless specifically stated.
For more details see our website www.sciencemediacentre.org,
please e-mail
the Science Media Centre with your comments.
|
|
|
